veneclax, chidaniline combined with azacitidine followed by decitabine + mag regimen in the treatment of elderly untreated aml

Conditions: Acute Myeloid Leukemia

Summary: a multicenter, prospective, single-arm clinical study of veneclax, chidaniline combined with azacitidine (vca) followed by decitabine + mag regimen (d-mag) in the treatment of elderly untreated acute myeloid leukemia (aml)

a multicenter, prospective, single-arm clinical study of veneclax, chidaniline combined with azacitidine (vca) followed by decitabine + mag regimen (d-mag) in the treatment of elderly untreated acute myeloid leukemia (aml)

Eligibility criteria:
inclusion criteria: 1. histologically confirmed acute myeloid leukemia (non-m3). have not received treatment before and cannot accept standard cytarabine and anthracycline induction regimen treatment due to age or comorbidity or patient preference; 2. age \>= 60 years old, male or female, expected survival time greater than 3 months; 3. estimated creatinine clearance \>= 30 ml/min; 4. ast and alt \<= 3.0 x uln (unless considered due to leukemic organ involvement). bilirubin \<= 1.5 x uln (unless considered due to leukemic organ involvement); 5. ecog \<= 2; 6. able to understand and voluntarily provide informed consent. exclusion criteria: 1. acute promyelocytic leukemia (apl) and low-risk cytogenetics, such as t(8;21), inv(16), or t(16;16); 2. active central nervous system leukemia; 3. a history of myeloproliferative neoplasms (mpn), including myelofibrosis, essential thrombocythemia, polycythemia vera, chronic myelogenous leukemia (cml) with or without bcr-abl1 translocation and aml with bcr- abl1 translocation; 4. hiv-positive patients and/or hbv or hcv active infection (documented by hbv-dna and hcv-rna positive tests); 5. suffering from chronic respiratory diseases requiring continuous oxygen inhalation, or having an obvious history of kidney, nervous system, psychiatric, endocrine, metabolic, immune, liver, and cardiovascular diseases; 6. suffering from malabsorption syndrome or other diseases that exclude the enteral route of administration; 7. clinically significant qtc interval prolongation (male \> 450 ms; female \> 470 ms), ventricular tachycardia and atrial fibrillation, second-degree heart block, myocardial infarction, and congestive heart failure within one year before enrollment patients, and patients with coronary heart disease who have clinical symptoms and need drug treatment; 8. active, uncontrolled severe infection; 9. there is a history of other malignant tumors within 2 years, except for the following cases: adequately treated carcinoma in situ of the cervix or carcinoma in situ of the breast; basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin; 10. white blood cell count \> 25 x 10\^9/l (hydroxyurea or leukapheresis can meet this standard); 11. mental disorders that will hinder research participation; 12. participants have received the following treatments: hypomethylation agents, venetoclax and/or chemotherapy for myelodysplastic syndrome (mds), solid organ transplantation; 13. any other circumstances that the investigator believes that the patient is not suitable to participate in this trial.